Retrieve available abstracts of 27 articles: HTML format
Single Articles
May 2025
SHAH M, Chen TY, Ison G, Fiero MH, et al Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose)
Polymerase Inhibitors in Advanced Ovarian Cancer.
J Clin Oncol. 2025 May 19:JCO2402834. doi: 10.1200/JCO-24-02834. PubMedAbstract available
January 2025
GAILLARD S, Lacchetti C, Armstrong DK, Cliby WA, et al Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO
Guideline Update.
J Clin Oncol. 2025 Jan 22:JCO2402589. doi: 10.1200/JCO-24-02589. PubMedAbstract available
December 2024
SCAMBIA G, Villalobos Valencia R, Colombo N, Cibula D, et al Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With
Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall
Survival Results.
J Clin Oncol. 2024 Dec 12:JCO2400933. doi: 10.1200/JCO.24.00933. PubMedAbstract available
November 2024
FAGOTTI A, Costantini B, Fanfani F, Giannarelli D, et al Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian
Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18).
J Clin Oncol. 2024 Nov 21:JCO2400686. doi: 10.1200/JCO.24.00686. PubMedAbstract available
October 2024
CHLEBOWSKI RT, Aragaki AK, Pan K, Haque R, et al Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term
Follow-Up of the Women's Health Initiative Randomized Trials.
J Clin Oncol. 2024;42:3537-3549. PubMedAbstract available
BERGSTROM EN, Abbasi A, Diaz-Gay M, Galland L, et al Deep Learning Artificial Intelligence Predicts Homologous Recombination
Deficiency and Platinum Response From Histologic Slides.
J Clin Oncol. 2024;42:3550-3560. PubMedAbstract available
LEE JM, Brady MF, Miller A, Moore RG, et al Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or
Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer:
NRG-GY005.
J Clin Oncol. 2024 Oct 3:JCO2400683. doi: 10.1200/JCO.24.00683. PubMedAbstract available
September 2024
GONZALEZ-MARTIN A, Rubio MJ, Heitz F, Depont Christensen R, et al Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent
Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO
69-O/ANITA Phase III Trial.
J Clin Oncol. 2024 Sep 18:JCO2400668. doi: 10.1200/JCO.24.00668. PubMedAbstract available
August 2024
O'BRIEN KM, Wentzensen N, Ogunsina K, Weinberg CR, et al Intimate Care Products and Incidence of Hormone-Related Cancers: A Quantitative
Bias Analysis.
J Clin Oncol. 2024;42:2645-2659. PubMedAbstract available
May 2024
LANDEN CN, Buckanovich RJ, Sill MW, Mannel RS, et al Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant
Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
J Clin Oncol. 2024 May 22:JCO2302076. doi: 10.1200/JCO.23.02076. PubMedAbstract available
HARRIS HR, Davis CP, Terry KL Epidemiologic Methods to Advance Our Understanding of Ovarian Cancer Risk.
J Clin Oncol. 2024 May 15:JCO2400602. doi: 10.1200/JCO.24.00602. PubMed
April 2024
MUTLU SUTCUOGLU B, Sutcuoglu O Interpretation of the EORTC-55954 Trial: Does the Response to Neoadjuvant
Chemotherapy Have an Effect on Disease Outcome?
J Clin Oncol. 2024;42:1204-1205. PubMed
HAN CY, Lu KH, Corrigan G, Perez A, et al Normal Risk Ovarian Screening Study: 21-Year Update.
J Clin Oncol. 2024;42:1102-1109. PubMedAbstract available
February 2024
LORUSSO D, Raspagliesi F, Ronzulli D, Valabrega G, et al Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With
Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A
Randomized Phase III Trial.
J Clin Oncol. 2024 Feb 5:JCO2301225. doi: 10.1200/JCO.23.01225. PubMedAbstract available
PAVLIK EJ, van Nagell JR Jr, Dietrich CS 3rd, Ueland FR, et al Compelling Story of Ovarian Cancer Screening.
J Clin Oncol. 2024 Feb 2:JCO2302424. doi: 10.1200/JCO.23.02424. PubMed
January 2024
TJOKROWIDJAJA A, Friedlander ML, Ledermann JA, Coleman RL, et al Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression
in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance
Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
J Clin Oncol. 2024 Jan 12:JCO2301182. doi: 10.1200/JCO.23.01182. PubMedAbstract available
November 2023
LAVERY JA, Boutros PC, Scott JM, Tammela T, et al Pan-Cancer Analysis of Postdiagnosis Exercise and Mortality.
J Clin Oncol. 2023;41:4982-4992. PubMedAbstract available
ST LAURENT J, Liu JF Treatment Approaches for Platinum-Resistant Ovarian Cancer.
J Clin Oncol. 2023 Nov 1:JCO2301771. doi: 10.1200/JCO.23.01771. PubMedAbstract available
October 2023
AREND RC, Monk BJ, Shapira-Frommer R, Haggerty AF, et al Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for
Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL
Study/GOG 3018).
J Clin Oncol. 2023 Oct 31:JCO2202915. doi: 10.1200/JCO.22.02915. PubMedAbstract available
September 2023
OZOLS RF, Bundy BN, Greer BE, Fowler JM, et al Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and
Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A
Gynecologic Oncology Group Study.
J Clin Oncol. 2023;41:4077-4083. PubMedAbstract available
SPRIGGS DR, Fleming GF Flashback Foreword: Cytoreductive Surgery for Ovarian Carcinoma and Carboplatin +
Paclitaxel in Ovarian Cancer.
J Clin Oncol. 2023;41:4063-4064. PubMed
August 2023
KURTZ JE, Pujade-Lauraine E, Oaknin A, Belin L, et al Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for
Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III
ATALANTE/ENGOT-ov29 Trial.
J Clin Oncol. 2023 Aug 29:JCO2300529. doi: 10.1200/JCO.23.00529. PubMedAbstract available
MCCAW ZR, Tian L, Wei LJ Evaluating the Duration of Response With Mirvetuximab Soravtansine for Treating
Platinum-Resistant Ovarian Cancer.
J Clin Oncol. 2023 Aug 3:JCO2300288. doi: 10.1200/JCO.23.00288. PubMed
June 2023
COLOMBO N, Van Gorp T, Matulonis UA, Oaknin A, et al Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant
Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
J Clin Oncol. 2023 Jun 26:JCO2202624. doi: 10.1200/JCO.22.02624. PubMedAbstract available
May 2023
KINNEY AY, Walters ST, Lin Y, Lu SE, et al Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk
Communication and Navigation Intervention: Large Effect Size but Room to Grow.
J Clin Oncol. 2023;41:2767-2778. PubMedAbstract available
STROOT IAS, Brouwer J, Bart J, Hollema H, et al High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in
Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical
Factors.
J Clin Oncol. 2023;41:2523-2535. PubMedAbstract available
March 2023
FU S, Yao S, Yuan Y, Previs RA, et al Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid
Tumors Harboring CCNE1 Amplification.
J Clin Oncol. 2023;41:1725-1734. PubMedAbstract available